# A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.

> **NCT00735085** · PHASE2 · TERMINATED · sponsor: **Abbott Products** · enrollment: 57 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** SLV334
- **DRUG:** SLV334
- **DRUG:** SLV334
- **DRUG:** SLV334
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00735085
- **Lead sponsor:** Abbott Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** This study was stopped 20 May 2010 due to strategic considerations
- **Last updated:** 2011-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735085, "A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00735085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*